FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology and genetic engineering, particularly to methods for genetic modification of hematopoietic cells. Presented is the use of prostaglandin E2 (PGE2), poloxamer and protamine sulphate for enhancing transduction by a recombinant retroviral vector.
EFFECT: compositions and methods according to the present invention can be used in gene therapy, including treatment of monogenic genetic diseases and disorders.
54 cl, 18 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENE THERAPY IN PATIENTS WITH FANCONI ANEMIA | 2017 |
|
RU2801241C2 |
| NUCLEIC ACID CONSTRUCTIONS AND VECTORS FOR GENOTHERAPY FOR TREATING WILSON'S DISEASE AND OTHER CONDITIONS | 2015 |
|
RU2745567C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2811426C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
